Creating a new generation of small molecule protease inhibitors for HAE and DME.
KalVista Pharmaceuticals, Inc. is a leading biopharmaceutical company dedicated to developing innovative oral medicines. KalVista Pharmaceuticals aims to empower individuals to enjoy everyday life, free from the constraints of their conditions. By leveraging profound expertise in the kallikrein-kinin system, KalVista Pharmaceuticals discovers, develops, and commercializes oral protease inhibitor drugs.
With a commitment to rigorous science, KalVista Pharmaceuticals is determined to better address the treatment needs of patients. Their primary investigational product, sebetralstat, targets hereditary angioedema (HAE), a rare genetic disease characterized by debilitating and potentially life-threatening tissue swelling. KalVista Pharmaceuticals, Inc. is headquartered at 55 Cambridge Pkwy, Cambridge, Massachusetts 02142, US.
KalVista Pharmaceuticals, Inc. is focused on making a meaningful difference in patient care. Management at KalVista Pharmaceuticals will soon complete the information regarding the company's full range of activities and product offerings. We invite the manager at KalVista Pharmaceuticals, Inc. to create a customized and exclusive company showcase and product listing on our platform.
Other organizations in the same industry
This company is also known as